Cargando…

Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout

Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jun Ho, Kim, Hyuk Soon, Lee, Jun-Ho, Yang, Gabsik, Kim, Hong Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967252/
https://www.ncbi.nlm.nih.gov/pubmed/35370689
http://dx.doi.org/10.3389/fphar.2022.861399
_version_ 1784678801530159104
author Lee, Jun Ho
Kim, Hyuk Soon
Lee, Jun-Ho
Yang, Gabsik
Kim, Hong Jun
author_facet Lee, Jun Ho
Kim, Hyuk Soon
Lee, Jun-Ho
Yang, Gabsik
Kim, Hong Jun
author_sort Lee, Jun Ho
collection PubMed
description Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long period of time due to the risk of side effects. Recent studies have shown that the modulation of MSU-induced inflammatory responses is dependent on the inflammatory cytokine IL-1β, which has a central role in a chain of processes involving multiple cytokines and mediators. In this regard, the NLRP3 inflammasome is known to play a crucial part and thus has been proposed as a novel target in the treatment for gout. However, the biochemical mechanism for NLRP3 inflammasome activation has not yet been clearly elucidated. Therefore, this report can provide an overview of natural extractions targeted to prevent or treat NLRP3 inflammasome-mediated gout in the MSU-induced gout model. In addition, the research and development of such natural products are suggested as a potential strategy in the treatment of gout.
format Online
Article
Text
id pubmed-8967252
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89672522022-03-31 Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout Lee, Jun Ho Kim, Hyuk Soon Lee, Jun-Ho Yang, Gabsik Kim, Hong Jun Front Pharmacol Pharmacology Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long period of time due to the risk of side effects. Recent studies have shown that the modulation of MSU-induced inflammatory responses is dependent on the inflammatory cytokine IL-1β, which has a central role in a chain of processes involving multiple cytokines and mediators. In this regard, the NLRP3 inflammasome is known to play a crucial part and thus has been proposed as a novel target in the treatment for gout. However, the biochemical mechanism for NLRP3 inflammasome activation has not yet been clearly elucidated. Therefore, this report can provide an overview of natural extractions targeted to prevent or treat NLRP3 inflammasome-mediated gout in the MSU-induced gout model. In addition, the research and development of such natural products are suggested as a potential strategy in the treatment of gout. Frontiers Media S.A. 2022-03-16 /pmc/articles/PMC8967252/ /pubmed/35370689 http://dx.doi.org/10.3389/fphar.2022.861399 Text en Copyright © 2022 Lee, Kim, Lee, Yang and Kim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lee, Jun Ho
Kim, Hyuk Soon
Lee, Jun-Ho
Yang, Gabsik
Kim, Hong Jun
Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
title Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
title_full Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
title_fullStr Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
title_full_unstemmed Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
title_short Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
title_sort natural products as a novel therapeutic strategy for nlrp3 inflammasome-mediated gout
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967252/
https://www.ncbi.nlm.nih.gov/pubmed/35370689
http://dx.doi.org/10.3389/fphar.2022.861399
work_keys_str_mv AT leejunho naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout
AT kimhyuksoon naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout
AT leejunho naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout
AT yanggabsik naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout
AT kimhongjun naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout